ABSTRACT: Peri-implant osteolysis is commonly diagnosed after substantial bone loss has occurred, making revision surgery more challenging. The goal of the current study was to identify urinary biomarkers that differentiate total hip replacement patients who eventually develop osteolysis from patients who do not. We used a repository of 24-h urine samples collected prior to surgery and annually thereafter in 26 patients, 16 who developed osteolysis, and 10 who did not. We examined the markers at radiographic diagnosis, annually for 6 years preceding diagnosis, at the first post-operative sampling point, and pre-operatively. Patients in the osteolysis and non-osteolysis groups were matched according to time post-surgery and did not differ in the male:female ratio or age at surgery. Seven candidate biomarkers were measured, including free deoxypyridinoline (DPD), cross-linked N-telopeptides (NTX), interleukin-6 (IL-6), interleukin-8 (IL-8), osteoprotegerin (OPG), a-crosslaps (a-CTX), and b-crosslaps (b-CTX). As an individual biomarker, DPD demonstrated the highest ability to predict osteolysis, with an area under the curve (AUC) in Receiver Operating Characteristic (ROC) analyses of 0.844 at 6 years prior to diagnosis. A panel of a-CTX and IL-6 was able to identify at-risk patients with an AUC of 0.941 or greater at all post-operative time points and an AUC of 1.000 pre-operatively. The results demonstrate the potential of using non-invasive biomarkers to identify patients at risk for peri-implant osteolysis long before the emergence of radiographic signs. Further, the high accuracy of the pre-operative biomarker levels demonstrates the potential importance of preexisting, patient-specific factors driving subsequent osteolysis. Study Design ß
The estimated number of patients in need of primary total joint replacement (TJR) surgery in the United States is projected to grow to over four million annually by the year 2030. 1 Revision surgeries are expected to grow at a similar rate, with more than 350,000 revision surgeries anticipated in the United States in the year 2030. 1 Aseptic loosening is one of the primary mechanisms contributing to failure of primary TJR. 2 Peri-implant osteolysis, induced by wear or corrosion products, is a key factor contributing to aseptic loosening. [3] [4] [5] Peri-implant osteolysis can progress asymptomatically, resulting in substantial bone loss, until mechanical failure of the bone-implant interface gives rise to symptoms (i.e., patient reported pain). Clinically, plain radiography is typically used for diagnosis, but detection of small osteolytic lesions is better served by cross-sectional imaging. 6 Currently, revision surgery is the only treatment for aseptic loosening caused by osteolysis. Revision surgeries are associated with higher failure rates, 7 higher patient mortality rates, 8 and worse pain and functional outcomes 9 than primary TJR. Substantial bone loss prior to revision surgery is a contributing factor to these poorer outcomes. 10 Diagnosing osteolysis prior to substantial bone loss could provide surgeons with the opportunity to perform revision surgery while the patient still maintains adequate bone mass. Additionally, preclinical studies have shown that biological and pharmacological treatment strategies are able to prevent osteolysis progression if initiated early. [11] [12] [13] Unfortunately, clinical trials to test early intervention strategies are lacking. Bisphosphonates, when given late in disease progression, have been tested clinically without success. 14 Interestingly, a registry study found that patients receiving long-term bisphosphonate treatment have a reduced rate of revision surgery, 15 implying that early intervention with this class of drugs may be an effective treatment strategy. One reason that few clinical trials have been initiated is the inability to identify patients at risk for osteolysis prior to radiographic diagnosis or patient reported pain.
Systemic biomarkers have shown considerable promise as a means to diagnose or monitor the response to treatment in musculoskeletal diseases such as osteoporosis. 16 The use of noninvasive or minimally invasive biomarkers to monitor patients post-surgery would provide real-time information on peri-implant inflammation or bone resorption, which in turn could be used to identify patients at risk for osteolysis. To date, biomarker studies in patients have been inconsistent and at times contradictory. 17 The major limitation of current biomarker research is that most studies only assess marker levels at the endstage of osteolysis. Therefore, there is little evidence that biomarkers can be used to predict osteolysis prior to implant failure. A single study has measured marker levels longitudinally and although the authors used early implant migration as a surrogate for eventual implant loosening, two of the biomarkers evaluated demonstrated early differences between stable and migrating implants. 18 The goal of the current study was to identify urinary biomarkers that differentiate total hip replacement patients who eventually develop osteolysis from patients that do not develop osteolysis. To do so, we used a longitudinal repository of 24-h urine samples obtained prospectively from patients undergoing THR. We compared biomarker concentrations in those patients who eventually developed radiographic osteolytic lesions to those patients who did not develop lesions. These measurements were made pre-operatively, early post-operatively, and annually up to 6 years before diagnosis.
MATERIALS AND METHODS

Study Design
The study design was approved by the institutional review board on human research. A signed consent form was obtained from each patient providing permission for storage of biofluids for future research studies.
A total of 26 patients undergoing primary THR by surgeons at Midwest Orthopedics at Rush that were recruited between 1989 and 1997 were used for this study. Twenty-four hours urine samples were used. The surgeon and implant materials varied (Supplemental Table S1 ). All patients received cementless porous coated acetabular components made from titanium alloy and had ultra-high molecular weight polyethylene (UHMWPE) liners. Eight patients received cementless titanium alloy hip stems, while the remaining 18 had cobalt chrome alloy stems (5 cemented and 13 cementless).
Patients had regular radiographic evaluation around the hip stem and acetabulum. Of the patients enrolled, 16 developed radiographic evidence of peri-implant osteolysis either adjacent to the hip stem or acetabular component and were assigned to the osteolysis group. The remaining 10 patients showed no signs of peri-implant osteolysis radiographically over the $19 year course of the follow-up period and were assigned to the non-osteolysis group.
Urine samples were synchronized according to the first reported radiographic lesion at either the acetabulum or the stem, which occurred an average of 90 (AE29) months post implantation. The sample taken at the time of diagnosis was classified as the diagnosis time-point, pre-operative samples were collected an average of 3 months prior to surgery, and the first post-operative samples were collected an average of 3 months after THR surgery. Samples collected at yearly intervals postsurgery were assigned to time points 6, 5, 4, 3, 2, and 1 year prior to radiographic diagnosis. Samples from non-osteolysis patients were matched according to the time post-implantation.
There were no significant differences between the nonosteolysis and osteolysis groups for sex or age at surgery ( Table 1 ). The sample size was not consistent at each time-point (Table 2) . At diagnosis and at the pre-operative time-point, we had the full complement of cases. Most of the missing data at the earlier time-points was due to lack of a 24-h urine sample. In addition, for two cases in the osteolysis group there were missing data at 6, 5, and/ or 4 years.
Radiographic Review
The date of radiographic diagnosis of osteolysis was obtained from clinical notes taken contemporaneously at the time of evaluation. Radiograph review was performed by a trained observer not involved in the current study according to wellvalidated techniques. The acetabulum was divided into three zones according to DeLee and Charnley. 19, 20 The femur was divided into seven zones as described by Gruen. 21 Osteolysis was defined as an area of localized loss of trabecular bone or cortical erosion that was not apparent on the pre-operative or immediate post-operative radiographs.
22,23
Biomarker Measurement Urine samples were frozen at À80˚C upon collection and subsequently thawed to aliquot for biomarker measurements. Before measurements, samples were manually mixed and centrifuged at 2,000g for 2 min to separate any agglomerates. Urinary concentrations were determined using commercially available ELISA assays. Candidate biomarkers measured included; free deoxypyridinoline (DPD, Quidel, San Diego, CA: intra-assay CV 8.4% and inter-assay CV 4.8%), crosslinked N-telopeptides (NTx, Alere, Orlando, FL, intra-assay CV 19% and inter-assay CV 5%), interleukin-6 (IL-6, Thermo, Waltham, MA, intra-assay CV <10%, inter-assay CV <10%), and interleukin-8 (IL-8, Thermo, Waltham, MA, intra-assay CV <10%, inter-assay CV <10%). Osteoprotegerin (OPG, Thermo, Waltham, MA, intra-assay CV <10%, interassay CV <12%), a crosslaps (a-CTX, Immunodiagnostics, Tyne & Wear, UK, intra-assay CV 2.3%, inter-assay CV 9.4%), and b crosslaps (b-CTX, Immunodiagnostics, Tyne & Wear, UK, intra-assay CV 3.9%, inter-assay CV 6.9%). Creatinine concentration was measured in the Rush Clinical Chemistry Laboratory using an Abbot Architect Immunoassay system (Abbott Architect c1600, Chicago, IL). All biomarker values were normalized by dividing by time-matched creatinine concentrations to account for kidney function.
Statistical Analysis
The data were summarized by descriptive statistics: mean and standard deviation for the continuous variable such as age and biomarker concentrations; frequency and percentage for the categorical variable such as gender. Creatinine normalized biomarker concentrations were compared between groups at each time-point using a non-parametric Mann-Whitney U-test. We also made between-group comparisons of biomarker values that had been normalized to both the time-matched creatinine and the pre-operative creatinine normalized measures, to account for inter-individual variation. It was determined that pre-operative normalization increased the between-group differences, and therefore all regression modeling was performed using the doubly normalized biomarker values. The ability of individual biomarkers to differentiate patients with osteolysis from patients without osteolysis was evaluated at each time-point using univariate logistic regression modeling. For ease of result interpretation biomarker concentrations were rescaled by each biomarker's interquartile range (IQR, the difference between 75th and 25th percentiles). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. The area (AUC) under the Receiver Operating Curve (ROC) was calculated to assess the discrimination power of each biomarker. The predictive value of the full panel of biomarkers (each weighted at 14.29%) was assessed at each time-point using multiple classification techniques, including logistic regression, Na€ve Bayes, Decision Tree, and Random Forests. A limited biomarker panel (subset of biomarkers) that was highly correlated with the classification (nonosteolysis or osteolysis) was chosen at the point of radiographic diagnosis. This limited panel was then tested at each time-point using the same classification strategy outlined above. At each time-point, the prediction accuracy, sensitivity, specificity, and AUC for each classification model were calculated. All the analyses were done using SAS 9.4 and WEKA 3.8. A two-sided test was used and a p-value < 0.05 was regarded as statistically significant.
RESULTS
Pre-operative levels of a-CTX (p ¼ 0.027) and IL-6 (p ¼ 0.020), were significantly depressed in the osteolysis group compared to the non-osteolysis group (Supplemental Table S2 ). Post-operative biomarker concentrations (normalized to the pre-op values) showed occasional between-group differences (Fig. 1) . Specifically, a-CTX was elevated in the osteolysis group compared to the non-osteolysis controls at 3 years prior to diagnosis (p ¼ 0.048) and at diagnosis (p ¼ 0.007). IL-6 levels were elevated in the osteolysis group at 6 (p ¼ 0.031) and 4 (p ¼ 0.048) years prior to diagnosis, and at diagnosis (p ¼ 0.014). The DPD concentration was lower in the osteolysis group compared to the non-osteolysis controls post-operatively (p ¼ 0.007) and at 6 (p ¼ 0.011) and 2 (p ¼ 0.027) years prior to diagnosis. OPG, NTX, b-CTX, and IL-8 levels were not different between the osteolysis and the nonosteolysis groups at any post-operative time point. Post-operative biomarker levels for each individual patient are plotted as Supplemental figures (Supplemental Figure S1a-g) .
The individual biomarker with the highest AUC varied across the time-points investigated (Table 3) . At diagnosis and 3 years prior to diagnosis, a-CTX had the highest individual AUC (0.809 and 0.773, respectively). IL-6 had the highest AUC pre-operatively (0.775) and at 1 (0.822), 4 (0.768), and 5 years prior to diagnosis (0.741). The highest individual AUC measured was DPD at 6 years prior to diagnosis (0.844), while the first sampling point after surgery (postoperative) was nearly as high (0.841). AUC results from the univariate logistic regression analysis for all biomarkers at each time-point evaluated are presented in detail in Supplemental Table S3 .
Despite normalizing the post-operative values to creatinine and the pre-operative value, there was considerable variability between patients and within patients over the 6 year follow-up. When the levels were not normalized to the pre-op values, almost none of the post-operative comparisons were significant (Supplemental Table S2 ). Therefore, all subsequent logistical modeling was performed using the pre-operative normalized biomarker values.
The use of all seven biomarkers (all normalized to their pre-operative values) in a panel dramatically increased the ability to distinguish the two groups (Table 4) . At diagnosis, pre-operatively, and at each time-point post-operatively, the biomarker panel demonstrated high accuracy, sensitivity, and specificity. The random forest classification strategy provided the greatest AUC at each time-point, but the results for each of the other classification strategies are presented in Supplemental Table S4 .
At diagnosis, a panel of a-CTX and IL-6 performed similarly to the panel including all seven biomarkers. Therefore, the two-marker panel was assessed at each time-point prior to diagnosis (Table 5 ). This limited panel performed comparably to the full panel with nearly the same accuracy sensitivity, specificity, and AUC.
DISCUSSION
The goal of the current study was to discover biomarkers that differentiate patients who developed osteolysis from those who did not develop osteolysis before conventional radiographic diagnosis. The largest between-group differences were noted in the pre-operative samples, while the largest AUC was found using the pre-operative biomarker levels of a panel of a-CTX and IL-6. Further, if normalized to pre-operative biomarker values, the AUC was 0.941 or greater at all post-operative time points using the two biomarker panel.
Results from this study demonstrate the importance of pre-operative biomarker levels in identifying patients at risk for peri-implant osteolysis. Peri-implant osteolysis is currently diagnosed via radiographic detection of peri-implant lesions, which are noticeable only after substantial bone loss. Revision surgery to replace failed implants is associated with worse outcomes than primary surgery 7-9 with loss of bone mass prior to revision being a contributing factor. 10 Identification of a biomarker or biomarker panel that could detect ongoing peri-implant osteolysis prior to substantial bone loss or even serve as a risk factor prior to surgery would allow for early intervention or motivate more detailed clinical monitoring. In the current study, we used a unique biorepository of urine samples collected prospectively in patients receiving primary total hip replacements. The repository was developed as part of a longitudinal study of metal release and transport from THRs of different fixation modalities and designs. 24, 25 The biomarkers tested in this study were primarily identified by a systematic review of the literature 17 and informed by previous work from our group using a rat model, 26 which we used to prioritize 10 candidate biomarkers. Of these 10 markers, TRAP 5b, cathepsin K, RANKL, and osteocalcin were not detected in urine using conventional ELISA assays. a-CTX was added as a candidate biomarker that was not originally identified in our systematic review, but has been shown to have considerable promise as a biomarker for cancer-related osteolysis. 27, 28 Of the seven biomarkers studied, a-CTX and IL-6, show the most promise for identifying at-risk patients. 
URINARY BIOMARKERS OF OSTEOLYSIS
Surprisingly, the biomarkers with the highest accuracy in identifying at risk patients were the pre-operative levels of a-CTX and IL-6. This result suggests that particular patients may be at greater risk for peri-implant osteolysis following THA. Indeed, genetic risk factors for susceptibility to osteolysis have recently been identified. 29, 30 Similar to the current study, IL-6 has been implicated, with a rare haplotype within IL-6 being positively associated with osteolysis 31 and single nucleotide polymorphisms in the IL-6 promotor have been reported to be predictive for aseptic loosening. 32 The addition of a-CTX as a predictive marker is in line with various studies that have demonstrated that pre-surgical remodeling rates contribute to the success of THA. 12, 33, 34 Because the pre-operative values provided the highest AUC in both the full panel and the limited panel outcomes and only pre-operative normalized data showed post-operative differences between groups, it is likely that the pre-operative values drove many of the postoperative results. Thus, pre-existing patient factors may determine susceptibility to the development of particulate-induced osteolysis.
The panel approach considerably increased the accuracy of the urinary biomarkers, likely due to the multi-factorial nature of peri-implant osteolysis. 35 The pathophysiology of peri-implant osteolysis involves an inflammatory response to wear particles, which activates bone resorption. 36 Therefore, it is not surprising to find increased accuracy when combining a marker of bone resorption, a-CTX, and one of inflammation, IL-6, compared to either marker alone. He et al. 37 similarly found that the combination of six biomarkers, including markers associated with both bone resorption and inflammation showed larger betweengroup differences at the time of diagnosis compared to any single biomarker alone. In the current study, we found that the combination of a-CTX and IL-6 provided diagnostic accuracy comparable to a panel of seven biomarkers.
C-terminal telopeptide of collagen type I, crosslaps, or CTX-I is a cross-linked fragment released from the alpha I collagen chain by osteoclastic resorption of the bone matrix. 38 CTX exists in two isoforms, a or b. Newly deposited collagen generally exists in the a, or non-isomerized form, which is isomerized to the b isoform as the bone matrix ages. 39 b-CTX is a commonly measured biomarker of osteoclastic bone resorption used to predict bone mass loss, response to treatment, and risk of osteoporotic fractures. 40 A previous study evaluating the utility of urinary b-CTX as a biomarker of peri-implant osteolysis reported no difference between groups, 41 which is consistent with results in the current study. a-CTX is emerging as a biomarker for osteolysis caused by the skeletal invasion of metastatic cancers, such as breast cancer. 27, 28 a-CTX is thought to reflect pathological skeletal remodeling wherein new bone is resorbed before it is able to isomerize into the b isoform. 42, 43 It is possible that the inflammatory response to particles causes resorption of new bone matrix, ultimately leading to the development of peri-implant osteolytic lesions. Urinary a-CTX has been previously studied in the context of peri-implant osteolysis at end-stage of the disease, but the authors noted no between-group differences. 44 In our study, a-CTX concentrations were significantly elevated at the point of radiographic osteolysis diagnosis. The reasons for this discrepancy are unknown, but may reflect differences in the study design, which include the use of second-morning void urine versus 24-h urine, or the increased average age of the patients evaluated in the study by Lawrence et al. 44 IL-6 is released by macrophages in response to implant particles 3, [45] [46] [47] [48] [49] [50] and various studies have demonstrated an increase in the number of IL-6 positive cells from interfacial tissues retrieved from patients with failed implants. [51] [52] [53] IL-6 has also been reported to be elevated in the serum of patients with osteolysis compared to controls. 54 Similar to a-CTX, the individual predictive value of IL-6 was moderate, with the between-group differences only becoming significant at 1 year prior to diagnosis. However, when a-CTX and IL-6 were combined in a panel, these two biomarkers demonstrated high accuracy for identifying patients at risk for osteolysis.
The current study is one of only two that has investigated biomarkers longitudinally in THR patients and the first to do so in samples collected before clinical diagnosis of osteolysis. The other longitudinal study found that biomarker levels, specifically osteocalcin and cross-linked carboxyterminal telopeptide of type I collagen (ICTP), were elevated before implant migration as assessed by radiosteriometric analsysis (RSA). 18 Early implant migration is considered a risk factor for late loosening 55 and, therefore, the authors concluded that early elevation in these biomarkers is predictive of future migration. In our study, patients were categorized based on routine radiographic analysis and therefore, biomarker levels in the current study relate directly to the clinical manifestation of osteolysis. Taken together, these two studies suggest it may be possible to identify patients at risk for subsequent implant loosening prior to conventional diagnostic strategies.
The primary limitation of the current study was the relatively small sample size, which limited our ability to construct independent training and validation sets. Thus, our focus was on discovery. Future validation work in independent cohorts is needed. 17 Additionally, the study suffered from missing values at various points during the longitudinal follow-up period, which prevented repeated measures statistics. To address this limitation, we normalized the biomarker measurements by the pre-operative value. It is also worth noting that the study included patients with variable implant designs. Although the cup and liner materials were consistent (titanium alloy with UHMPE, respectively), the manufacturer was not consistent, nor was the stem material consistent as both titanium and CoCr alloys were used. This heterogeneity in implant materials likely impacted our ability to detect between-group differences. However, the ability to accurately identify patients at risk for osteolysis in spite of design variability provides more clinical utility to the biomarkers tested.
Despite the encouraging results presented in the current study, there remain many challenges in the clinical translation of osteolysis biomarkers, including the needed validation studies and the lack of longitudinal data sets. Future, large-scale validation efforts will likely need to take the form of similar efforts currently underway in the field of osteoarthritis, [56] [57] [58] which has engaged stakeholders to outline the pathway toward biomarker validation and importantly have funded large-scale longitudinal biorepositories.
Clinically, it is envisioned that biomarker measurements, once validated, could serve as a compliment to routine radiographic surveillance. Further, if patients at risk for subsequent osteolysis development could be identified at an early stage, this at-risk group could be designated for more intensive monitoring, in an effort to identify complications prior to substantial bone loss. Finally, although there are currently no validated treatment options for peri-implant osteolysis apart from revision surgery, several preclinical animal models have identified pharmacological agents able to prevent or reverse osteolysis if treatment is initiated early. [11] [12] [13] If biomarkers are validated, it is possible that they could motivate future pharmaceutical clinical trials by identifying patients either at risk for osteolysis or early in disease progression, for recruitment into such trials. In addition, validated biomarkers can be used as a method to monitor response to any pharmacological intervention as they are more sensitive than radiographic studies.
We evaluated the use of urinary biomarkers to identify patients who developed peri-implant osteolysis prior to radiographic diagnosis. Although single biomarkers showed moderate accuracy, the combination of a-CTX, a bone resorption marker, and IL-6, an inflammatory marker, lead to high accuracy in the differentiation of patients who eventually developed peri-implant osteolysis from those with no signs of osteolysis. Future work is necessary to test these markers in independent cohorts and to determine their clinical utility as a means to predict osteolysis prior to substantial peri-implant bone loss.
